For the first time in 2012, the monthly growth figure for pharma industry has dropped to single digit in November to 4.1%. However, for the period of 12 month ended November, the growth is intact at 15.4% for the domestic pharma industry.
For the month of November, the top two companies by market share — Abbott and Cipla — have witnessed negative growth of -5.8% and -0.5%, according to pharma marketing research firm Aiocd Awacs. Six of the top 10 companies, have either clocked single digit growth or have registered negative growth. The only four companies in the top 10 that saw growth in double digit include Sun Pharma, Zydus Cadila, Ranbaxy Labs and Mankind. The rate of growth has been pulled back by the sluggish growth of vitamins and minerals and gastrointestinal segments and negative growth of therapies such as analgesics(pain reliever market), gynaeocological segment, opthalmological segment and anti-malarial segment.
Hari Natarajan, head, analytics, Aiocd Awacs said that the slow growth was more accentuated in North and Eastern India. Number of holidays in the festive season in this period could have affected the patient pool adversely leading to a slowdown in the market, he added.
The domestic pharma industry on a 12 month ended November basis reached a size of R69,296 crore. Defying the slowdown, the anti-diabetic market grew at 15.6% while the cardiac segment grew at 8.0%. On the other hand, the anti-infective market clocked a growth of 3.3% whereas respiratory market grew 3.9%.